Débora Cabral de Carvalho Corrêa1,2, Indhira Dias Oliveira1, Bruna Mascaro Cordeiro1, Frederico Adolfo Silva1,3, Maria Teresa de Seixas Alves1,4, Nasjla Saba-Silva1, Andrea Maria Capellano1, Patrícia Dastoli1, Sergio Cavalheiro1,5, Silvia Regina Caminada de Toledo6,7. 1. Department of Pediatrics, Pediatric Oncology Institute-GRAACC, Federal University of São Paulo, São Paulo, SP, Brazil. 2. Department of Morphology and Genetics, Division of Genetics, Federal University of São Paulo, São Paulo, SP, Brazil. 3. Department of Imaging Diagnosis, Federal University of São Paulo, São Paulo, SP, Brazil. 4. Department of Pathology, Federal University of São Paulo, São Paulo, SP, Brazil. 5. Department of Neurology, Federal University of São Paulo, São Paulo, SP, Brazil. 6. Department of Pediatrics, Pediatric Oncology Institute-GRAACC, Federal University of São Paulo, São Paulo, SP, Brazil. silviatoledo@graacc.org.br. 7. Department of Morphology and Genetics, Division of Genetics, Federal University of São Paulo, São Paulo, SP, Brazil. silviatoledo@graacc.org.br.
Abstract
PURPOSE: In neurogenesis, ASPM (abnormal spindle-like microcephaly-associated) gene is expressed mainly in the ventricular zone of posterior fossa and is the major determinant in the cerebral cortex. Besides its role in embryonic development, ASPM overexpression promotes tumor growth, including central nervous system (CNS) tumors. This study aims to investigate ASPM expression levels in most frequent posterior fossa brain tumors of childhood and adolescence: medulloblastoma (MB), ependymoma (EPN), and astrocytoma (AS), correlating them with clinicopathological characteristics and tumor solid portion size. METHODS: Quantitative reverse transcription (qRT-PCR) is used to quantify ASPM mRNA levels in 80 pre-treatment tumor samples: 28 MB, 22 EPN, and 30 AS. The tumor solid portion size was determined by IOP-GRAACC Diagnostic Imaging Center. We correlated these findings with clinicopathological characteristics and tumor solid portion size. RESULTS: Our results demonstrated that ASPM gene was overexpressed in MB (p = 0.007) and EPN (p = 0.0260) samples. ASPM high expression was significantly associated to MB samples from patients with worse overall survival (p = 0.0123) and death due to disease progression (p = 0.0039). Interestingly, two patients with AS progressed toward higher grade showed ASPM overexpression (p = 0.0046). No correlation was found between the tumor solid portion size and ASPM expression levels in MB (p = 0.1154 and r = - 0.4825) and EPN (p = 0.1108 and r = - 0.3495) samples. CONCLUSION: Taking in account that ASPM gene has several functions to support cell proliferation, as mitotic defects and premature differentiation, we suggest that its overexpression, presumably, plays a critical role in disease progression of posterior fossa brain tumors of childhood and adolescence.
PURPOSE: In neurogenesis, ASPM (abnormal spindle-like microcephaly-associated) gene is expressed mainly in the ventricular zone of posterior fossa and is the major determinant in the cerebral cortex. Besides its role in embryonic development, ASPM overexpression promotes tumor growth, including central nervous system (CNS) tumors. This study aims to investigate ASPM expression levels in most frequent posterior fossa brain tumors of childhood and adolescence: medulloblastoma (MB), ependymoma (EPN), and astrocytoma (AS), correlating them with clinicopathological characteristics and tumor solid portion size. METHODS: Quantitative reverse transcription (qRT-PCR) is used to quantify ASPM mRNA levels in 80 pre-treatment tumor samples: 28 MB, 22 EPN, and 30 AS. The tumor solid portion size was determined by IOP-GRAACC Diagnostic Imaging Center. We correlated these findings with clinicopathological characteristics and tumor solid portion size. RESULTS: Our results demonstrated that ASPM gene was overexpressed in MB (p = 0.007) and EPN (p = 0.0260) samples. ASPM high expression was significantly associated to MB samples from patients with worse overall survival (p = 0.0123) and death due to disease progression (p = 0.0039). Interestingly, two patients with AS progressed toward higher grade showed ASPM overexpression (p = 0.0046). No correlation was found between the tumor solid portion size and ASPM expression levels in MB (p = 0.1154 and r = - 0.4825) and EPN (p = 0.1108 and r = - 0.3495) samples. CONCLUSION: Taking in account that ASPM gene has several functions to support cell proliferation, as mitotic defects and premature differentiation, we suggest that its overexpression, presumably, plays a critical role in disease progression of posterior fossa brain tumors of childhood and adolescence.
Authors: Jennifer L Fish; Yoichi Kosodo; Wolfgang Enard; Svante Pääbo; Wieland B Huttner Journal: Proc Natl Acad Sci U S A Date: 2006-06-23 Impact factor: 11.205
Authors: Tânia M Vulcani-Freitas; Najsla Saba-Silva; Andréa Cappellano; Sérgio Cavalheiro; Sueli K N Marie; Sueli M Oba-Shinjo; Suzana M F Malheiros; Sílvia Regina Caminada de Toledo Journal: Childs Nerv Syst Date: 2010-08-06 Impact factor: 1.475
Authors: S Horvath; B Zhang; M Carlson; K V Lu; S Zhu; R M Felciano; M F Laurance; W Zhao; S Qi; Z Chen; Y Lee; A C Scheck; L M Liau; H Wu; D H Geschwind; P G Febbo; H I Kornblum; T F Cloughesy; S F Nelson; P S Mischel Journal: Proc Natl Acad Sci U S A Date: 2006-11-07 Impact factor: 11.205
Authors: Scott E Williams; Idoia Garcia; Andrew J Crowther; Shiyi Li; Alyssa Stewart; Hedi Liu; Kendall J Lough; Sean O'Neill; Katherine Veleta; Esteban A Oyarzabal; Joseph R Merrill; Yen-Yu Ian Shih; Timothy R Gershon Journal: Development Date: 2015-10-08 Impact factor: 6.868
Authors: A Brüning-Richardson; J Bond; R Alsiary; J Richardson; D A Cairns; L McCormack; R Hutson; P Burns; N Wilkinson; G D Hall; E E Morrison; S M Bell Journal: Br J Cancer Date: 2011-04-19 Impact factor: 7.640